Teenagers are buying a prescription bladder cancer medication online to increase their height, prompting urgent safety warnings from physicians across the medical community.
Doctors warn that teenagers, particularly boys, are experimenting with erdafitinib in a viral social media trend known as “heightmaxxing.” The prescription drug, sold under the brand name Balversa, is strictly authorized by the Food and Drug Administration to treat advanced forms of bladder cancer.
Specialists emphasize that utilizing an oncology medication for cosmetic growth carries severe physical risks. These include potential damage to bone growth plates, persistent pain, and organ dysfunction.
“It is extremely alarming that adolescents are experimenting with powerful oncological drugs in an attempt to grow taller.”
Dr. Stephanie Widmer, an emergency medicine physician in New York, told Fox News Digital.
Erdafitinib works by blocking the activity of a protein that stimulates the development of tumor cells. This protein is present in both tumor cells and other cells in the body. By inhibiting it, the drug slows tumor growth. Pharmaceutical manufacturer Johnson & Johnson said that the medication is not approved for pediatric use or for height enhancement, and its safety and efficacy for such purposes remain unestablished.
Interest in the drug's off-label potential surged following a study published in 2024 in the journal Hormone Research in Paediatrics. Researchers observed unexpected growth spurts in children receiving the medication for central nervous system tumors.
| Clinical Parameter | Approved Indication | Off-Label Adolescent Use (“Heightmaxxing”) |
|---|---|---|
| Target Population | Adults with advanced urothelial carcinoma | Teenagers seeking height increase |
| Acquisition Method | On-label prescription via licensed pharmacies | Unregulated online sellers outside the US |
| Documented Side Effects | Ocular disorders, stomatitis, nail dystrophies | Joint pain, severe nosebleeds, nail infection |
Puberty naturally drives skeletal elongation through growth plates near the ends of bones. Medical specialists stress that chemical agents cannot reopen closed plates, rendering the drug ineffective for height gain post-puberty while exposing users to systemic toxicity.
Reports indicate that minors have successfully acquired the restricted substance through international online vendors. Patients reported experiencing severe joint pain, chronic nosebleeds, and nail bed infections accompanied by purulent discharge during self-administration.
Johnson & Johnson confirmed that the therapy is prescribed strictly to patients with urothelial carcinoma—which accounts for roughly 90 percent of annual bladder cancer diagnoses—whose disease has progressed despite prior systemic treatments. Common side effects in clinical trials include hyperphosphatemia, vision impairment, and musculoskeletal discomfort.
The medication is contraindicated for pediatric patients and anyone seeking cosmetic alterations. Anyone who has ingested unprescribed oncological agents must seek immediate medical evaluation.
Immediate clinical intervention is warranted if a patient develops severe bone pain, vision changes, signs of metabolic imbalance, or severe joint swelling following unverified drug exposure. Pediatricians and emergency physicians must be informed of all online substances ingested by minors to properly manage acute toxicities.
Medical professionals urge families to prioritize long-term systemic health over aesthetic goals. Unverified pharmacological experiments during developmental years risk causing permanent physiological damage.
“Nary a centimetre is worth the risk of permanently impairing your vision or facing severe, compounding medical complications whose longitudinal effects we simply do not yet know.”
Widmer told Daily Mail.
- Hormone Research in Paediatrics: Studies on FGFR inhibition and pediatric bone development (2024).
- U.S. Food and Drug Administration (FDA): Balversa (erdafitinib) prescribing information and oncological approvals.
- Fox News Digital: Clinical reports on adolescent misuse of oncology drugs.
- Rolling Stone: Investigative reporting on online acquisition of restricted substances by minors.
